Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Invested Capital (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Invested Capital for 4 consecutive years, with $740.7 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 6.83% to $740.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $740.7 million through Dec 2025, down 6.83% year-over-year, with the annual reading at $740.7 million for FY2025, 6.83% down from the prior year.
  • Invested Capital hit $740.7 million in Q4 2025 for NewAmsterdam Pharma, down from $772.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $800.9 million in Q1 2025 to a low of $301.0 million in Q4 2023.
  • Historically, Invested Capital has averaged $543.5 million across 4 years, with a median of $444.9 million in 2024.
  • Biggest five-year swings in Invested Capital: plummeted 39.62% in 2023 and later soared 164.15% in 2024.
  • Year by year, Invested Capital stood at $498.5 million in 2022, then tumbled by 39.62% to $301.0 million in 2023, then skyrocketed by 164.15% to $795.0 million in 2024, then fell by 6.83% to $740.7 million in 2025.
  • Business Quant data shows Invested Capital for NAMS at $740.7 million in Q4 2025, $772.4 million in Q3 2025, and $799.4 million in Q2 2025.